NASDAQ:KZR Kezar Life Sciences (KZR) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free KZR Stock Alerts $0.90 +0.01 (+1.12%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.85▼$0.9150-Day Range$0.80▼$1.0552-Week Range$0.67▼$3.66Volume560,244 shsAverage Volume904,810 shsMarket Capitalization$65.74 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kezar Life Sciences alerts: Email Address Kezar Life Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,118.2% Upside$11.00 Price TargetShort InterestBearish4.64% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.72Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.19 out of 5 starsMedical Sector172nd out of 939 stocksPharmaceutical Preparations Industry67th out of 435 stocks 3.2 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Kezar Life Sciences has a forecasted upside of 1,118.2% from its current price of $0.90.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.64% of the outstanding shares of Kezar Life Sciences have been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Kezar Life Sciences has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kezar Life Sciences is -0.85. Previous Next 3.7 News and Social Media Coverage News SentimentKezar Life Sciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.Search Interest3 people have searched for KZR on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to remain at ($1.17) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Kezar Life Sciences Stock (NASDAQ:KZR)Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More KZR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZR Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comHead to Head Analysis: Kezar Life Sciences (NASDAQ:KZR) & Humanigen (NASDAQ:HGEN)March 27, 2024 | investorplace.comFrom Pennies to Fortunes: 3 Stocks Set to Make MillionairesMarch 28, 2024 | DTI (Ad)Buy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.March 20, 2024 | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Increase in Short InterestMarch 19, 2024 | americanbankingnews.comKezar Life Sciences' (KZR) Buy Rating Reaffirmed at HC WainwrightMarch 16, 2024 | investorplace.comDiamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026March 14, 2024 | investorplace.comKZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023March 14, 2024 | businesswire.comKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 12, 2024 | finanznachrichten.deEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for NefeconMarch 3, 2024 | finance.yahoo.comKezar Life Sciences, Inc. (KZR)February 28, 2024 | finance.yahoo.comKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese MarketFebruary 26, 2024 | businesswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 26, 2024 | prnewswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 22, 2024 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and DatesFebruary 19, 2024 | thestreet.comKezar Life Sciences Inc.February 10, 2024 | finance.yahoo.com3 Penny Stocks Poised for an Unbelievable 1,000% JumpJanuary 31, 2024 | morningstar.comKezar Life Sciences Inc KZRJanuary 18, 2024 | finance.yahoo.comKZR Jan 2025 17.500 callDecember 26, 2023 | finance.yahoo.comBull Run Bonanza: Top 3 Penny Stocks Primed for Explosive GrowthDecember 5, 2023 | msn.comEverest inches towards clinical studies for renal disease drug in ChinaNovember 27, 2023 | markets.businessinsider.comBuy Rating Affirmed: Kezar Life Sciences’ Promising Trials and Strong FinancialsNovember 27, 2023 | markets.businessinsider.comAnalyst Expectations for Kezar Life Sciences's FutureNovember 21, 2023 | finance.yahoo.comKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2023 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR), Analyst Ratings, Price Targets, PredictionsSee More Headlines Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KZR CUSIPN/A CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,118.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,870,000.00 Net MarginsN/A Pretax Margin-1,455.29% Return on Equity-43.08% Return on Assets-37.59% Debt Debt-to-Equity Ratio0.05 Current Ratio11.66 Quick Ratio11.66 Sales & Book Value Annual Sales$7 million Price / Sales9.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.35Miscellaneous Outstanding Shares72,800,000Free Float67,050,000Market Cap$65.74 million OptionableNot Optionable Beta0.48 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Christopher J. Kirk Ph.D. (Age 51)Co-Founder, CEO & Director Comp: $677.41kMr. John Franklin Fowler (Age 52)Co-Founder & Director Comp: $919.91kDr. Jack Taunton Ph.D.Co-FounderMr. Marc L. Belsky (Age 69)CFO & Secretary Comp: $491.79kMs. Gitanjali JainVice President of Investor Relations & External AffairsMr. Mark SchillerChief Legal OfficerDr. Neel K. Anand Ph.D.Senior Vice President of Research & Drug DiscoveryDr. Nick Mordwinkin Ph.D. (Age 43)Pharm.D., Chief Business Officer & Head of Strategy Mr. Zung ToSenior Vice President of Clinical DevelopmentMs. Pattie ChiangVP & Corporate ControllerMore ExecutivesKey CompetitorsEagle PharmaceuticalsNASDAQ:EGRXKorro BioNASDAQ:KRROAnebulo PharmaceuticalsNASDAQ:ANEBMediciNovaNASDAQ:MNOVLandos BiopharmaNASDAQ:LABPView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 22,917 shares on 3/11/2024Ownership: 4.214%Goldman Sachs Group Inc.Sold 942,285 shares on 3/1/2024Ownership: 0.609%GSA Capital Partners LLPBought 260,407 shares on 2/16/2024Ownership: 0.358%Vanguard Group Inc.Bought 22,917 shares on 2/15/2024Ownership: 4.214%Citadel Advisors LLCSold 28,600 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions KZR Stock Analysis - Frequently Asked Questions Should I buy or sell Kezar Life Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares. View KZR analyst ratings or view top-rated stocks. What is Kezar Life Sciences' stock price target for 2024? 3 brokers have issued 12-month target prices for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,118.2% from the stock's current price. View analysts price targets for KZR or view top-rated stocks among Wall Street analysts. How have KZR shares performed in 2024? Kezar Life Sciences' stock was trading at $0.9474 at the beginning of the year. Since then, KZR shares have decreased by 4.7% and is now trading at $0.9030. View the best growth stocks for 2024 here. When is Kezar Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KZR earnings forecast. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) released its earnings results on Tuesday, November, 9th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL). When did Kezar Life Sciences IPO? Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO. Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (6.91%), Vanguard Group Inc. (4.21%), Vanguard Group Inc. (4.21%), Granahan Investment Management LLC (2.62%), Northern Trust Corp (0.75%) and Goldman Sachs Group Inc. (0.61%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment. View institutional ownership trends. How do I buy shares of Kezar Life Sciences? Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KZR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.